- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1346
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease |
|---|---|
| Other Thrombin Products | Thrombomodulin Antibody [A4N7] Befovacimab (Anti-TFPI) |
|
In vitro |
Water : 162 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | Formula | (C12H16NS2Na3)20 |
Storage (From the date of receipt) | ||
|---|---|---|---|---|---|
| CAS No. | 9041-08-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCC1CC(N[R])C(OC1CO[S]([O-])(=O)=O)OC2C(O)C(O)C(OC3C(CO[R])OC(OC4C(O)C(O[S]([O-])(=O)=O)C(OC5C(O)C(N[S]([O-])(=O)=O)C(C)OC5CO[S]([O-])(=O)=O)OC4C([O-])=O)C(N[S]([O-])(=O)=O)C3[S]([O-])(=O)=O)OC2C([O-] | ||
| Targets/IC50/Ki |
Antithrombin III
|
|---|---|
| In vitro |
Heparin is widely used as an anticoagulant drug based on its ability to accelerate the rate at which antithrombin inhibits serine proteases in the blood coagulation cascade. Heparin and the structurally related heparan sulfate are complex linear polymers comprised of a mixture of chains of different length, having variable sequences. Heparin interactes most tightly with peptides containing a complementary binding site of high positive charge density. Heparin and heparan sulfate predominantly exhibit linear helical secondary structures with sulfo and carboxyl groups displayed at defined intervals and in defined orientations along the polysaccharide backbone. Heparin resembles DNA as both are highly charged linear polymers that behave as polyelectrolytes. Heparin is believed to function as an anticoagulant primarily through its interaction with AT III by enhancing AT-III-mediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin binds to AT III and thrombin in a ternary complex, increasing the bimolecular rate constant for the inhibition of thrombin by a factor of 2000. Heparin is principally located in the granules of tissue mast cells that are closely associated with the immune response. Heparin makes numerous contacts with both FGF-2 and FGFR-1 stabilizing FGF–FGFR binding. Heparin also makes contacts with the FGFR-1 of the adjacent FGF–FGFR complex, thus seeming to promote FGFR dimerization. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.